DLD Asset Management’s Cytokinetics CYTK Stock Holding History

DLD Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,000	Closed	-$605K	–	402
2025 Q3	$605K	Buy	+11,000	New	+$453K	0.04%	204

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DLD Asset Management's CYTK Position: Q4 2025 in Review

DLD Asset Management sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 11,000 shares — an estimated $605K sold.

DLD Asset Management first reported a position in CYTK in Q3 2025 and held it in 1 quarter. The position peaked at $605K in Q3 2025. 431 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

DLD Asset Management reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
DLD Asset Management sold 11,000 Cytokinetics shares in Q4 2025, an estimated $605K.
DLD Asset Management first reported a position in Cytokinetics in Q3 2025 and held it in 1 quarter.
DLD Asset Management's Cytokinetics position peaked at $605K in Q3 2025.
431 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.